MedTrace Logo

Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

NCT05529355 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2022-09-07

No results posted yet for this study

Summary

The trial was a randomized, open-label, multicenter Phase II study of patients with advanced or metastatic NSCLC who don't harbor driver genes. The aim is to explore the efficacy and safety of Envafolimab Combined With Endostar/S-1 in second-line treatment of advanced non-small cell lung cancer.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Envafolimab plus Endostar and S-1

Immunotherapy combined with chemotherapy and anti VEGFR therapy

DRUG

Envafolimab plus Endostar

Immunotherapy combined with anti VEGFR therapy

DRUG

Envafolimab plus S-1

Immunotherapy combined with chemotherapy

Sponsors & Collaborators

  • Anhui Chest Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-18
Primary Completion
2023-09-18
Completion
2023-09-18

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05529355 on ClinicalTrials.gov